Evista /Raloxifene Hydrochloride
group nameAnti Estrogen Steroid
-
Min Order10 gram
brand nameJNJG
model82640-04-8
payment methodL/C, Western Union, MoneyGram, T/T, Bitcoin
-
update timeFri, 17 Mar 2017 11:25:44 GMT
Paramtents
CAS NO 82640-04-8
MF C28H29NO4S
MW 475.5992
Purity 99%
Appearance White powder
Certification ISO 9001, USP, BP
Standard USP
Usage For osteoporosis prevention of postmenopausal wome
Packging & Delivery
Min Order10 gram
Briefing
Detailed
Evista /Raloxifene Hydrochloride
EMAIL: cgf at chembj dot com
Skype: cgf..........com
Whatsapp: +8615564141272
CAS No: 82640-04-8
Molecular Formula: C28H29NO4S
Molecular Weight: 475.5992
Appearance: White powder
Purity: 99%
Certification: ISO 9001, USP, BP
Specification: USP
Uses: For osteoporosis prevention of postmenopausal women.
Description:
Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.
Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).
Application:
Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
Advantage:
2. Our products have exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Australia, Japan, Korea and many other countries, over 100kgs each month.
3. Professional team special for package and shipment and staring on tracking code 24hours for customs pass guaranteed. 100% pass to UK, Norway, Poland, Spain, USA, Canada, Brazil; 98% pass to Germany, Russia, Australia, New Zealand.
4. Most of powders are in stock, Chargeable samples are available, Could be shipped out within 24hours.
5. High quality, good price, fast and safety delivery. Shipment by DHL, TNT, FEDEX, HKEMS, UPS, etc.
You need a product
Related Searches
You May Like
6YRS Jinan Jiage Biological Technology Co,Ltd
- Nearest port for product export
- shenzhen, shanghai
- Delivery clauses under the trade mode
- FOB
- Acceptable payment methods
- T/T, L/C, D/P D/A, MoneyGram, Credit Card, PayPal, Westem Union, Cash, Escrow